| Name | Title | Contact Details |
|---|
HOB is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baxter International Inc. through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Pleomorphic Product Sales is a Glendale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens® Contact Hearing Solution, which directly vibrates the eardrum with a tiny lens in order to activate the natural hearing process. This revolutionary, nonsurgical hearing solution delivers the broadest bandwidth available today and superior sound quality. The Earlens® Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. We believe that people with hearing loss shouldn`t have to think about their hearing in everyday situations. Earlens was designed specifically to address the sound quality and speech understanding complaints that are common among hearing aid wearers and contribute to non-compliance. We make every Earlens device custom-fit for each patient`s unique anatomy and hearing needs, while offering modern features such as Bluetooth streaming.
Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel`s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.